← All trials
NCT02502903
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 1, 2015
- Primary completion
- Jun 17, 2018
- Completion date
- Oct 1, 2018
- First posted
- —
- Last posted
- —
- Enrollment
- 98
- Arms / groups
- 3 / —
- Source
- AACT · pre-existing
Sponsors
- True North TherapeuticsLead sponsor
- University of ViennaOverall official - principal investigator
- Assign Clinical Research GmbHCollaborator
- Vela LaboratoriesCollaborator
- ABF Pharmaceutical Services GmbHCollaborator
- Quest DiagnosticsCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.